Status:
COMPLETED
The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants
Lead Sponsor:
Zhengzhou Children's Hospital, China
Conditions:
Efficacy and Safety
Eligibility:
All Genders
1-96 years
Phase:
NA
Brief Summary
Bronchopulmonary dysplasia (BPD) is the most prevalent longterm morbidity among surviving extremely preterm infants and has a multifactorial etiology. BPD is associated with later risk of reactive air...
Eligibility Criteria
Inclusion
- gestational age\<32 weeks,
- \<96 hours of age
Exclusion
- genetic metabolic diseases;
- congenital major abnormalities;
- congenital non-bacterial infection with overt signs at birth;
- terminal stage of illness (pH \< 7.0 or hypoxia with bradycardia\>2 h);
- ≥ grade III intracranial hemorrhage;
- lacking parental consent.
Key Trial Info
Start Date :
July 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 28 2020
Estimated Enrollment :
676 Patients enrolled
Trial Details
Trial ID
NCT03779776
Start Date
July 1 2018
End Date
June 28 2020
Last Update
September 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhengzhou Children's Hospital
Zhengzhou, Henan, China, 450018